Top developments and predictions in the Life Sciences & Healthcare sector in Asia-Pacific


In this round-up, we look back at the top developments over the last 12 months in the life sciences & healthcare sector, and we look to the future with our top predictions for the coming year for businesses operating in the Asia-Pacific region.

In 2022, mainland China continued its legal reform of the LSHC, complementing and echoing the 2019 revision of the Drug Administration Law, by establishing a drug-reporting system, introducing specific regulations for the management of medical devices and vaccines, and improving the regulation of online drug sales. Elsewhere in the region, the Hong Kong government is promoting telehealth services and Singapore has updated regulations on patient safety, laboratory development tests and the labelling of beverages.

This year, mainland China expects to see the implementation of two important pieces of legislation and new regulations on the development of biopharmaceuticals and in response to the ageing population. In Hong Kong, the government is expected to further introduce innovative technology in public healthcare services. In Singapore, legislators are planning to create a cybersecurity labelling scheme for medical devices, and in general create tighter rules, greater clarity and transparency in healthcare regulatory regimes.

Our experts will be closely monitoring these ongoing developments and predictions during the course of the year, and will provide regular updates and analysis through our various free platforms: the eAlert service, Law-Now, LinkedIn at ‘CMS Asia Pacific and CMS Life Sciences & Healthcare Sector’ and WeChat at ‘CMSAsia’.

We hope you find our reflections on 2022 and predictions for the future of interest as you continue to look to the year ahead.